Table 2 Summary of meta-analysis outcomes for Japanese type 2 diabetes patients with low (<8 %) and high (≥8 %) baseline HbA1c levels
From: Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis
Outcome | Effect estimate | 95 % Confidence limits | p value | Effect estimate | 95 % Confidence limits | p value | ||
|---|---|---|---|---|---|---|---|---|
Lower | Upper | Lower | Upper | |||||
Low (<8 %) baseline HbA1c | High (≥8 %) baseline HbA1c | |||||||
Change in HbA1c (%) | −0.80 | −1.18 | −0.43 | <0.0001 | −1.19 | −1.46 | −0.92 | <0.0001 |
Change in weight (kg) | −0.62 | −1.72 | 0.49 | 0.28 | −0.17 | −0.68 | 0.34 | 0.52 |
Change in FPG (mg/dL) | −12.5 | −30.9 | 5.8 | 0.18 | −14.7 | −25.9 | −3.6 | 0.0097 |
Change in PPG: meal test (mg/dL) | −132.0 | −171.7 | −92.4 | <0.0001 | −162.0 | −185.9 | −138.1 | <0.0001 |
Odds ratio | 95 % Confidence limits | p value | Odds ratio | 95 % Confidence limits | p value | |||
|---|---|---|---|---|---|---|---|---|
Lower | Upper | Lower | Upper | |||||
Low (<8 %) baseline HbA1c | High (≥8 %) baseline HbA1c | |||||||
Symptomatic hypoglycemia | 2.9 | 0.8 | 10.0 | 0.10 | 2.9 | 1.2 | 7.1 | 0.0229 |
Severe hypoglycemia | 0.0 | 0.0 | 0.0 | – | 0.0 | 0.0 | 0.0 | – |
Endpoint HbA1c <7 % | 25.5 | 5.2 | 124.6 | <0.0001 | 15.8 | 2.9 | 85.6 | 0.0014 |
Endpoint HbA1c <7 % and no weight gain | 15.8 | 3.3 | 75.8 | 0.0005 | 10.0 | 1.8 | 55.9 | 0.0091 |
Endpoint HbA1c <7 % and no symptomatic hypoglycemia | 11.8 | 2.0 | 68.7 | 0.0060 | 11.1 | 2.0 | 61.8 | 0.0059 |
Endpoint HbA1c <7 % and no weight gain and no symptomatic hypoglycemia | 8.9 | 1.5 | 52.2 | 0.0154 | 6.4 | 1.1 | 38.6 | 0.0430 |